trending Market Intelligence /marketintelligence/en/news-insights/trending/mbrcuhmij4rw6qii11z2ya2 content esgSubNav
In This List

Aileron Therapeutics CEO resigns; interim replacement named

Blog

Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage

Video

COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021

Blog

Corporate Credit Risk Trends in Developing Markets: A Loss Given Default (LGD) Perspective

Blog

Corporate Credit Risk Trends in Developing Markets: A Probability of Default Perspective


Aileron Therapeutics CEO resigns; interim replacement named

Joseph Yanchik III resigned as president, CEO and director of Aileron Therapeutics Inc.

The clinical-stage biopharmaceutical company named John Longenecker as interim CEO. Longenecker is the founder and president of JPL Biotech, a biopharma/pharmaceutical consulting company.